Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.
biznews.com2h
🔒 FT: Weight-loss drugs reduce risk of Alzheimer’s, large study shows
A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.
Despite low obesity rate, Mass. has the third-highest increase in weight-loss drug prescriptions nationwide. Why?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
ScienceAlert8h
Ozempic: Weight-Loss Drug's Benefits And Risks Revealed in New Study
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
Obesity Drug Study Points to Effectiveness in Curbing Addictions
One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...
Study Shows Diabetes Drugs' Potential Beyond Weight Loss
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...